Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum

globenewswire.com
NERV The article announces the company's participation in a virtual forum. It provides factual information about the event and the company's ongoing Phase 3 trial but does not offer any new insights or performance indicators that would suggest a strong bullish or bearish sentiment.

Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum BURLINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in The Stifel 2026 Virtual CNS Forum being held March 17-18, 2026.

If you are interested in a virtual meeting with the Minerva team during the conference, please reach out to your Stifel representative.

A replay of the presentation will be available on the Company's Investors & Media Events and Presentations webpage for ninety days following the event.

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is initiating a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s website.

Contacts:

Investor inquiries:

Frederick Ahlholm

Chief Financial Officer

Minerva Neurosciences, Inc.

FAhlholm@minervaneurosciences.com

Corey Davis, Ph.D.

LifeSci Advisors, LLC

212-915-2577

cdavis@lifesciadvisors.com